Altered Patterns of Early Metabolic Decompensation in Type 1 Diabetes During Treatment with a SGLT2 Inhibitor: An Insulin Pump Suspension Study.

about

SGLT inhibitor adjunct therapy in type 1 diabetes

P2860

Q58718282-03F4C6A9-7650-40B3-B2B5-EA82A6919534

P2860

Altered Patterns of Early Metabolic Decompensation in Type 1 Diabetes During Treatment with a SGLT2 Inhibitor: An Insulin Pump Suspension Study.

Item

http://www.wikidata.org/entity/Q47722005

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Altered Patterns of Early Meta ...... Insulin Pump Suspension Study.

@en

Altered Patterns of Early Meta ...... Insulin Pump Suspension Study.

@nl

type

Item

label

Altered Patterns of Early Meta ...... Insulin Pump Suspension Study.

@en

Altered Patterns of Early Meta ...... Insulin Pump Suspension Study.

@nl

prefLabel

Altered Patterns of Early Meta ...... Insulin Pump Suspension Study.

@en

Altered Patterns of Early Meta ...... Insulin Pump Suspension Study.

@nl

P1476

Altered Patterns of Early Meta ...... Insulin Pump Suspension Study.

@en

P2093

Jennifer L Sherr

http://www.w3.org/2001/XMLSchema#string

Lori R Carria

http://www.w3.org/2001/XMLSchema#string

Michelle A Van Name

http://www.w3.org/2001/XMLSchema#string

Neha S Patel

http://www.w3.org/2001/XMLSchema#string

Stuart A Weinzimer

http://www.w3.org/2001/XMLSchema#string

P2860

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

SGLT2 Inhibitors May Predispose to Ketoacidosis

Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry.

Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition

Dapagliflozin as an adjunct therapy to insulin in the treatment of patients with type 1 diabetes mellitus.

Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1)

SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects.

8. Pharmacologic Approaches to Glycemic Treatment.

The Effect of Canagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, on Glycemic End Points Assessed by Continuous Glucose Monitoring and Patient-Reported Outcomes Among People With Type 1 Diabetes.

SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function

P304

618-622

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1089/DIA.2017.0267

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

William V Tamborlane

Eda Cengiz

P577

2017-10-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29068709

http://www.w3.org/2001/XMLSchema#string

P921

type-1 diabetes

P932

5689123

http://www.w3.org/2001/XMLSchema#string

Altered Patterns of Early Metabolic Decompensation in Type 1 Diabetes During Treatment with a SGLT2 Inhibitor: An Insulin Pump Suspension Study.

about

P2860

P2860

Altered Patterns of Early Metabolic Decompensation in Type 1 Diabetes During Treatment with a SGLT2 Inhibitor: An Insulin Pump Suspension Study.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932